Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 16/20 | 0.70 |
| ▸ | DRD2 | P14416 | 15/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 1/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7556929 | 0.89 | DRD4 (0.74) | DRD4DRD2HTR1AHTR2AADORA2A | |
| SCHEMBL5419042 | 0.89 | DRD4 (0.74) | DRD4DRD2HTR1AHTR2AADORA2A | |
| SCHEMBL7632544 | 0.89 | DRD4 (0.70) | DRD4DRD2HTR1AHTR2AADORA2A | |
| SCHEMBL6906393 | 0.89 | DRD4 (0.70) | DRD4DRD2HTR1AHTR2AADORA2A | |
| SCHEMBL6903337 | 0.87 | DRD4 (0.73) | DRD4DRD2HTR1AHTR2AADORA2A | |
| SCHEMBL7628544 | 0.87 | DRD4 (0.73) | DRD4DRD2HTR1AHTR2AADORA2A | |
| SCHEMBL5414093 | 0.86 | DRD4 (0.85) | DRD4DRD2HTR1AHTR2A | |
| SCHEMBL14533026 | 0.86 | DRD4 (0.85) | DRD4DRD2HTR1AHTR2A | |
| SCHEMBL5403039 | 0.86 | DRD4 (0.69) | DRD4DRD2HTR1AHTR2AADORA2A | |
| SCHEMBL5417646 | 0.85 | DRD4 (0.73) | DRD4DRD2HTR1AHTR2AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048869-A1 | Combination treatment for depression, anxiety and psychosis | PFIZER INC | 2004-03-11 | — | — | US | claimed |
| US-20020094986-A1 | Combination treatment for depression, anxiety and psychosis | PFIZER INC | 2002-07-18 | — | — | US | claimed |
| EP-1213031-A2 | Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist | Pfizer Products Inc. (US) | 2002-06-12 | — | — | EP | claimed |
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ZORN STEVIN H (US) | 2002-05-02 | — | — | US | claimed |
| EP-1201268-A2 | Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | claimed |
| EP-0783503-B1 | 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO[ 1,2-A]PYRAZINE DERIVATIVES | PFIZER (US) | 2001-11-28 | — | — | EP | claimed |
| US-5852031-A | 2,7-substituted octahydro-1H-pyrido 1,2-a!pyrazine derivatives | PFIZER INC. (US) | 1998-12-22 | — | — | US | claimed |
| US-20040048869-A1 | Combination treatment for depression, anxiety and psychosis | PFIZER INC | 2004-03-11 | — | — | US | disclosed |
| US-20020094986-A1 | Combination treatment for depression, anxiety and psychosis | PFIZER INC | 2002-07-18 | — | — | US | disclosed |
| EP-1213031-A2 | Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist | Pfizer Products Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ZORN STEVIN H (US) | 2002-05-02 | — | — | US | disclosed |
| EP-1201268-A2 | Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| EP-0783503-B1 | 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO[ 1,2-A]PYRAZINE DERIVATIVES | PFIZER (US) | 2001-11-28 | — | — | EP | disclosed |
| US-5852031-A | 2,7-substituted octahydro-1H-pyrido 1,2-a!pyrazine derivatives | PFIZER INC. (US) | 1998-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094986-A1 | Combination treatment for depression, anxiety and psychosis | HTR4, CHRNA4, GRM4 | DRD4 4/4885DRD2 6/4885HTR1A 12/4885 |
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ACHE, BCHE, CHRM4 | DRD4 31/4885DRD2 35/4885HTR1A 155/4885 |
| US-20040048869-A1 | Combination treatment for depression, anxiety and psychosis | HTR4, CHRNA4, GRM4 | DRD4 4/4885DRD2 6/4885HTR1A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.